Literature DB >> 16423853

The anti-angiogenic VEGF isoform VEGF165b transiently increases hydraulic conductivity, probably through VEGF receptor 1 in vivo.

C A Glass1, S J Harper, D O Bates.   

Abstract

Vascular endothelial growth factor (VEGF) is the principal agent that increases microvascular permeability during physiological and pathological angiogenesis. VEGF is differentially spliced to form two families of isoforms: VEGF(xxx), and VEGF(xxx)b. Whereas VEGF(165) stimulates angiogenesis, VEGF(165)b is anti-angiogenic. To determine the effect of VEGF(165)b on permeability, hydraulic conductivity (L(p)) was measured in individually perfused microvessels in the mesentery of frogs and rats. As with VEGF(165), VEGF(165)b increased L(p) in amphibian (2.4 +/- 0.3-fold) and mammalian (1.9 +/- 0.2-fold) mesenteric microvessels. A dose-response relationship showed that VEGF(165)b (EC(50), 0.65 pm) was approximately 25 times more potent than VEGF(165) (EC(50), 16 pm) in amphibian microvessels. VEGF(165) has been shown to increase permeability through VEGF receptor 2 (VEGF-R2) signalling. However, VEGF(165)b increased L(p) of frog vessels to the same extent in the presence of the VEGF-R2 inhibitor ZM323881, indicating that it does not increase permeability via VEGF-R2 signalling, and was inhibited by the VEGF receptor inhibitor SU5416 at doses that are specific for VEGF receptor 1 (VEGF-R1). VEGF(165)b, in contrast to VEGF(165), did not result in a sustained chronic increase in L(p). These results show that although VEGF(165)b is anti-angiogenic in the mesentery, it does signal in endothelial cells in vivo resulting in a transient, but not sustained, increase in microvascular L(p), probably through VEGF-R1.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16423853      PMCID: PMC1779637          DOI: 10.1113/jphysiol.2005.103127

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  36 in total

Review 1.  Vascular endothelial growth factor and microvascular permeability.

Authors:  D O Bates; D Lodwick; B Williams
Journal:  Microcirculation       Date:  1999-06       Impact factor: 2.628

2.  Cytosolic Ca2+ concentration and rate of increase of the cytosolic Ca2+ concentration in the regulation of vascular permeability in Rana in vivo.

Authors:  C A Glass; T M Pocock; F E Curry; D O Bates
Journal:  J Physiol       Date:  2005-02-17       Impact factor: 5.182

3.  A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability.

Authors:  S A Stacker; A Vitali; C Caesar; T Domagala; L C Groenen; E Nice; M G Achen; A F Wilks
Journal:  J Biol Chem       Date:  1999-12-03       Impact factor: 5.157

4.  Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor.

Authors:  R M Perrin; O Konopatskaya; Y Qiu; S Harper; D O Bates; A J Churchill
Journal:  Diabetologia       Date:  2005-09-29       Impact factor: 10.122

5.  VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression.

Authors:  Jeanette Woolard; Wen-Ying Wang; Heather S Bevan; Yan Qiu; Lucia Morbidelli; Rowan O Pritchard-Jones; Tai-Gen Cui; Marto Sugiono; Elizabeth Waine; Rachel Perrin; Rebecca Foster; Jonathon Digby-Bell; Jacqueline D Shields; Cheryl E Whittles; Rosey E Mushens; David A Gillatt; Marina Ziche; Steven J Harper; David O Bates
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

6.  VEGF induces NO-dependent hyperpermeability in coronary venules.

Authors:  H M Wu; Q Huang; Y Yuan; H J Granger
Journal:  Am J Physiol       Date:  1996-12

7.  Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate.

Authors:  M J Tolentino; J W Miller; E S Gragoudas; F A Jakobiec; E Flynn; K Chatzistefanou; N Ferrara; A P Adamis
Journal:  Ophthalmology       Date:  1996-11       Impact factor: 12.079

8.  Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor.

Authors:  A Sawano; T Takahashi; S Yamaguchi; M Aonuma; M Shibuya
Journal:  Cell Growth Differ       Date:  1996-02

Review 9.  Vascular endothelial growth factor (VEGF) and its receptors.

Authors:  G Neufeld; T Cohen; S Gengrinovitch; Z Poltorak
Journal:  FASEB J       Date:  1999-01       Impact factor: 5.191

10.  The chronic effect of vascular endothelial growth factor on individually perfused frog mesenteric microvessels.

Authors:  D O Bates
Journal:  J Physiol       Date:  1998-11-15       Impact factor: 5.182

View more
  27 in total

1.  Murine rVEGF164b, an inhibitory VEGF reduces VEGF-A-dependent endothelial proliferation and barrier dysfunction.

Authors:  Walter Cromer; Merilyn H Jennings; Yoshinubo Odaka; J Michael Mathis; J Steven Alexander
Journal:  Microcirculation       Date:  2010-10       Impact factor: 2.628

2.  VEGF165b Modulates Endothelial VEGFR1-STAT3 Signaling Pathway and Angiogenesis in Human and Experimental Peripheral Arterial Disease.

Authors:  Vijay Chaitanya Ganta; Min Choi; Anna Kutateladze; Brian H Annex
Journal:  Circ Res       Date:  2016-12-14       Impact factor: 17.367

3.  Hypoxia inducible factor-1α (HIF-1α) and some HIF-1 target genes are elevated in experimental glaucoma.

Authors:  Ceren Ergorul; Arjun Ray; Wei Huang; Dan Yi Wang; Yixin Ben; Ippolita Cantuti-Castelvetri; Cynthia L Grosskreutz
Journal:  J Mol Neurosci       Date:  2010-03-17       Impact factor: 3.444

Review 4.  Therapeutic potential of manipulating VEGF splice isoforms in oncology.

Authors:  Emma S Rennel; Steven J Harper; David O Bates
Journal:  Future Oncol       Date:  2009-06       Impact factor: 3.404

Review 5.  Vascular endothelial growth factors and vascular permeability.

Authors:  David O Bates
Journal:  Cardiovasc Res       Date:  2010-04-16       Impact factor: 10.787

6.  Investigation of antiangiogenic tumor therapy potential of microencapsulated HEK293 VEGF165b producing cells.

Authors:  Fatemeh Afkhami; Yves Durocher; Satya Prakash
Journal:  J Biomed Biotechnol       Date:  2010-10-14

Review 7.  The role of VEGF 165b in pathophysiology.

Authors:  Maria Peiris-Pagès
Journal:  Cell Adh Migr       Date:  2012-10-17       Impact factor: 3.405

8.  VEGF modulation of retinal pigment epithelium resistance.

Authors:  Zsolt Ablonczy; Craig E Crosson
Journal:  Exp Eye Res       Date:  2007-08-24       Impact factor: 3.467

9.  The effects of inflammatory cytokines on lymphatic endothelial barrier function.

Authors:  Walter E Cromer; Scott D Zawieja; Binu Tharakan; Ed W Childs; M Karen Newell; David C Zawieja
Journal:  Angiogenesis       Date:  2013-10-20       Impact factor: 9.596

10.  Failure to up-regulate VEGF165b in maternal plasma is a first trimester predictive marker for pre-eclampsia.

Authors:  Victoria L Bills; Julia Varet; Ann Millar; Steven J Harper; Peter W Soothill; David O Bates
Journal:  Clin Sci (Lond)       Date:  2009-02       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.